SaniSure

Stories /
Healthcare /
SaniSure /

Five acquisitions in 12 months

Created one of the largest independent single-use solutions platforms in the bioprocessing industry through innovation and buy-and-build

Investment date

2019 – Current

Good to great

c.50%

Sales CAGR 2020-2022

Launching innovative, proprietary solutions serving high-value customer needs in critical process steps

Five

acquisitions completed in the first 12 months

Completed five acquisitions in first 12 months to form the global platform, accelerating each acquired business’ international growth

1,000+

pharmaceutical, CDMO and biotech customers

Increasing portfolio exposure to the high-growth biologics and cell and gene therapy markets

Investing to support commercial and operational excellence initiatives to better serve our customers

Key events under our ownership

Created a unified, vertically-integrated platform in the high-growth bioprocessing space by bringing together Cellon, Silicone Altimex, and TBL Performance Plastics

Refined commercial strategy to focus the platform on providing innovative solutions for high-criticality SUT applications for leading biopharma, biotech companies, and CDMOs

Brought Sani-Tech West into the platform, enhancing the size of the combined business and creating a global leader with well-established operations and reach in North America and Europe

Leveraged sector expertise and network to recruit key management members to complement the founders and other existing leaders

Introduced first proprietary product innovation, Mixed4Sure, which underscores R&D capabilities and enhances brand perception – highly focused on offering differentiated / proprietary innovations within the product portfolio

Acquired the Twinsburg facility, a leading silicone extrusion facility in late 2022, further developing SaniSure as a leading provider of critical fluid path technologies